Aspergillosis
Conditions
Keywords
GM monitoring, Immunocompromised, hematological disorder, Allogenic HSCT recipients, Aspergillus PCR assay
Brief summary
Chemotherapy lowers the white blood cell count or weakens the immune system for a long time. This puts the patients at a high risk of getting a serious fungal infection of the internal organs or blood. One of these infections is caused by a mold called Aspergillus and can be life threatening. Usually doctors give preventive antifungal therapy to try to lower the risk of this infection. Despite this, patients are still at risk of getting fungal infection. This study is thus designed to test Galactomannan - a component of cell wall of Aspergillus and hence detect and treat fungal infection early.
Detailed description
The diagnosis of invasive Aspergillosis (IA) remains a challenge in the febrile neutropenic and the hematopoietic stem cell transplant (HSCT) recipients. Recent studies have shown that early diagnosis of IA is possible in this group of high-risk patients. Serial screening of circulating Galactomannan (GM), an epitopic determinant of several antigens secreted by the Aspergillus early in its growth, has been shown to be sensitive and specific in the diagnosis of IA. This test may help us to detect IA early, thereby permitting a pre-emptive strategy to be initiated in high-risk patients. In a prospective, randomized, non-blinded study, we seek to compare the outcome of a novel GM-guided anti-fungal strategy against the conventional empirical antifungal therapy. Patients randomized to the conventional arm will not undergo serial GM monitoring, but will receive standard anti-fungal prophylaxis and standard empirical antifungal therapy in accordance with published guidelines. Patients randomized to the GM arm will receive standard anti-fungal prophylaxis but will not receive empiric anti-fungal therapy unless 2 GM readings are positive. The study aims to determine if such a strategy permits targeted, pre-emptive therapy in those at greatest risk, and spare febrile patients without evidence of fungal infection other than prolonged fever from unnecessary and potentially toxic therapy. It also aims to determine if GM guided pre-emptive antifungal therapy using Amphotericin-B deoxycholate prevents the development of proven or probable invasive aspergillosis (IA). The study will also prospectively evaluate (in a blinded fashion) the use of realtime polymerase chain reaction (RT PCR) assay in the same cohort of patients receiving GM serial monitoring, and investigate its role in the diagnosis and treatment monitoring of invasive Aspergillosis.
Interventions
BEHAVIORALGalactomannan antigen monitoring, Aspergillus PCR
There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
OTHERblood draws
Blood is drawn for monitoring of Galactomannan antigen in the blood
OTHERblood draws for GM monitoring
blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
DRUGAmphotericin-B deoxycholate
1-1.5mg/kg, i.v, once a day
OTHERblood test
Blood will be tested twice a week for the presence of Galactomannan.
OTHERBlood test
Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
Sponsors
National University Hospital, Singapore
Singapore General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with newly diagnosed acute leukemia or high risk myelodysplastic syndrome (MDS) receiving induction chemotherapy with expected duration of neutropenia (absolute neutrophil count of \< 500/mL) of at least 10 days 2. Patients with relapsed acute leukemia or MDS receiving salvage chemotherapy with expected duration of neutropenia (absolute neutrophil count of \< 500/mL) of at least 10 days 3. Patients with severe aplastic anemia (SAA) receiving chemotherapy or immunosuppressive therapy using antithymocyte globulin 4. Patients receiving allogeneic/autologous hematopoeitic stem cell transplant (HSCT) using myeloablative conditioning regimens 5. Patients are at least 12 years of age, with Karnofsky score of 70%.? 6. Patients on consolidation chemo regimens like HIDAC and HyperCVAD type B with expected duration of neutropenia (ANC \< 500/ml) of at least 10 days
Exclusion criteria
1. Patients who are human immunodeficiency virus (HIV) infected 2. Patients with uncontrolled bacteremia or active pulmonary infection at the time of randomisation 3. Patients with pre-existing proven and probable invasive fungal infections, according to the definitions of the invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Disease \[10\]. 4. Patients receiving concomitant piperacillin/tazobactam or co-amoxyclavulinic acid 5. Patients on palliative chemotherapy 6. Patients with history of allergy to triazoles 7. Patients with prior history of anaphylactic reaction to conventional amphotericin B 8. Patients with serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, or bilirubin more than 5 times the upper limit of normal or renal impairment with calculated creatinine clearance \< 30ml/min 9. Patients with expected life-expectancy \< 72 hours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of proven or probable invasive fungal infection, fungal related mortality and overall survival in an intention to treat basis. | During neutropenia, or, in HSCT patients, while under immunosuppressive therapy |
Secondary
| Measure | Time frame |
|---|---|
| Duration of antifungal therapy and toxicity associated with antifungal therapy. | while patient is on follow-up. |
Countries
Singapore
Outcome results
None listed